Category News

Jumar Bioincubator: Pioneering Mini Brain & Lab-on-a-Chip Tech to Create Australia’s Next CSL

Australia’s Newest Biotech Incubator, Jumar Bioincubator, Opens with Ambitious Ventures Jumar Bioincubator has officially launched in Melbourne, welcoming its first cohort of 16 pioneering early-stage ventures. The event, graced by Lord Mayor Sally Capp AO, showcased the cutting-edge facilities and…

Read MoreJumar Bioincubator: Pioneering Mini Brain & Lab-on-a-Chip Tech to Create Australia’s Next CSL

NEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING

Peptide manufacturing for commercial-scale production primarily employs two main methodologies: synthetic and recombinant. Each method presents unique advantages and challenges, crucial for stakeholders in the pharmaceutical industry to consider when determining the most suitable production strategy. In this article, we’ll…

Read MoreNEXT GENERATION PEPTIDE DRUGS FAVOR SYNTHETIC, NOT RECOMBINANT MANUFACTURING

Supporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone

The rising cost of living compounds the difficulties faced by low-income families with children, creating an urgent need for support, says Heidi Herranen, Coordinator of Save the Children Finland’s Fuel for Life Programme. Orion’s donation of EUR 50,000, split between…

Read MoreSupporting Save the Children Finland: Orion’s Donation Ensures No Child or Young Person Copes Alone

Updated Terminology for Airborne Pathogens Released by Leading Health Agencies

In collaboration with public health agencies and experts worldwide, the World Health Organization (WHO) has released a comprehensive report introducing updated terminology for pathogens transmitted through the air. The report, titled “Global Technical Consultation Report on Proposed Terminology for Airborne…

Read MoreUpdated Terminology for Airborne Pathogens Released by Leading Health Agencies

FINTLEPLA®▼ (fenfluramine) oral solution gains approval in Japan as adjunctive therapy for seizures linked with Lennox-Gastaut syndrome (LGS)

UCB’s FINTEPLA®▼ (fenfluramine) oral solution has received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating seizures linked with Lennox-Gastaut syndrome (LGS) as an additional therapy alongside other anti-epileptic medications for patients aged two and above.…

Read MoreFINTLEPLA®▼ (fenfluramine) oral solution gains approval in Japan as adjunctive therapy for seizures linked with Lennox-Gastaut syndrome (LGS)

Six-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients

Novartis has unveiled findings from the ALITHIOS open-label extension study, spotlighting the enduring effectiveness of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing multiple sclerosis (RMS). This group, characterized by commencing treatment within…

Read MoreSix-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients

WuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024

WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”) in recognition of its outstanding sustainability performance throughout 2023. The…

Read MoreWuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024

Comparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

TheracosBio has recently published a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled, phase 3 trial” in the Journal of…

Read MoreComparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

Jazz Pharmaceuticals to Present Comprehensive Neuroscience Portfolio at Annual American Academy of Neurology Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that its expansive neuroscience portfolio and pipeline will be prominently featured at the 76th Annual American Academy of Neurology Meeting (AAN), taking place from April 13-18, 2024, in Denver. A total of 13…

Read MoreJazz Pharmaceuticals to Present Comprehensive Neuroscience Portfolio at Annual American Academy of Neurology Meeting